US 12,122,782 B2
Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators
Kwame Wiredu Nti-Addae, Tewksbury, MA (US); Leena Kumari Prasad, San Francisco, CA (US); and Thomas Storz, Lowell, MA (US)
Assigned to Tisento Therapeutics Inc., Cambridge, MA (US)
Filed by Tisento Therapeutics Inc., Cambridge, MA (US)
Filed on Sep. 28, 2022, as Appl. No. 17/954,713.
Application 17/954,713 is a continuation of application No. 16/976,430, filed on Aug. 27, 2020, granted, now 11,466,015, issued on Oct. 11, 2022.
Application 16/976,430 is a continuation of application No. PCT/US2019/021080, filed on Mar. 7, 2019.
Claims priority of provisional application 62/639,846, filed on Mar. 7, 2018.
Prior Publication US 2023/0095799 A1, Mar. 30, 2023
Int. Cl. A61K 31/4985 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [C07B 2200/13 (2013.01)] 31 Claims
 
1. A crystalline Hydrate 2 of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine of the formula:

OG Complex Work Unit Chemistry
(i) wherein the crystalline Hydrate 2 is characterized by a powder X-ray diffraction pattern comprising at least three diffraction peaks at diffraction angles (°2θ) selected from the group consisting of 10.4°±0.2 °2θ, 15.50±0.2 °2θ, 18.4°±0.2 °2θ, 18.7°±0.2 °2θ, and 21.9°±0.2 °2θ; or
(ii) wherein the crystalline Hydrate 2 is characterized by a powder X-ray diffraction pattern comprising at least three diffraction peaks at diffraction angles (°2θ) selected from the group consisting of 7.3°±0.2 °2θ, 10.6°±0.2 °2θ, 15.8°±0.2 °2θ, 15.9°±0.2 °2θ, and 27.6°±0.2 °2θ.
 
30. A pharmaceutical composition comprising the crystalline Hydrate 2 of claim 1 and a pharmaceutically acceptable carrier or diluent.